Effect of flaxseed oil supplementation on the erythrocyte membrane fatty acid composition and endocannabinoid system modulation in patients with coronary artery disease: a double-blind randomized controlled trial

• Published in: Genes & nutrition 2020-05, Vol.15 (1), p.9-9, Article 9
• Main Authors: Saleh-Ghadimi, Sevda, Alizadeh, Mohammad, Jafari-Vayghan, Hamed, Darabi, Masoud, Golmohammadi, Ali, Kheirouri, Sorayya
• Format: Article
• Language: English
• Subjects: Arachidonic acid; Atherosclerosis; Blood; Body mass index; Cannabinoid CB1 receptors; Cannabinoid CB2 receptors; Cardiovascular disease; Clinical trials; Coronary artery; Coronary vessels; Diet; Dietary supplements; Double-blind studies; Drug dosages; Endocannabinoid system; Ethanolamine; Fatty acid composition; Fatty acids; Fatty-acid amide hydrolase; Fish oils; Gas chromatography; Gene expression; Heart diseases; Hydrolase; Inflammation; Ligands; Linoleic acid; Linolenic acid; Milk; Oils & fats; Phospholipids; Placebos; Risk factors; Tumor necrosis factor-TNF; Vegetable oils
• ISSN: 1555-8932; 1865-3499
• DOI: 10.1186/s12263-020-00665-1

The endocannabinoid system (ECS) overactivation, associated with increased inflammatory process, may act as a risk factor for coronary artery disease (CAD). Dietary fat may influence the ECS tone. The aim of the present study was to investigate the effect of flaxseed oil on the erythrocyte membrane fatty acid profile and ECS activity by the measurement of serum N-arachydonoil ethanolamine (AEA) and cannabinoid receptor type-1 (CB1), cannabinoid receptor type-2 (CB2), and fatty acid amide hydrolase (FAAH) mRNA expression. This clinical trial was performed on 44 patients with CAD. The intervention group received 1.5% fat milk supplemented with flaxseed oil (containing 2.5 g α-linolenic acid or ALA), while the placebo group received 1.5% fat milk for 10 weeks. The fatty acid profile of erythrocyte membrane phospholipids was measured by gas chromatography. The AEA level was determined using an ELISA kit, and real-time PCR was performed to measure CB1, CB2, and FAAH mRNA expression pre- and post-intervention. Flaxseed oil supplementation resulted in a significant increase in the ALA content and a significant reduction in linoleic acid (LA) content of membrane phospholipids, compared to the placebo group (MD = - 0.35 and 2.89, respectively; P < 0.05). The within group analysis showed that flaxseed oil supplementation caused a significant reduction in both LA and arachidonic acid (MD = - 4.84 and - 4.03, respectively; P < 0.05) and an elevation in the ALA (MD = 0.37, P < 0.001) content of membrane phospholipids compared with the baseline. In the intervention group, a marked reduction was observed in the serum AEA level after 10 weeks of intervention, compared with the placebo group (MD = 0.64, P = 0.016). Changes in CB2 mRNA expression in the flaxseed oil group were significant (fold change = 1.30, P = 0.003), compared with the placebo group. Flaxseed oil supplementation could attenuate the ECS tone by decreasing the AEA level and increasing CB2 mRNA expression. Therefore, flaxseed oil may be considered a promising agent with cardioprotective properties.